Table 3.
Baseline scores
| Clinical trial | Treatment groups | na | Cognition scale | ADL scale | Global assessment | Depression scale | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Kanowski et al33,34 | EGb 240 mg | 106 | SKT | 10.5 (3.2) | NAB | 21.5 (3.8) | CGI (item 1) | 4.8 (0.8) | MADRS | 15.7 (7.2) |
| Placebo | 99 | 11.2 (3.3) | 21.1 (3.7) | 4.7 (0.8) | 16.2 (7.2) | |||||
| Le Bars et al30,31 | EGb 120 mg | 155 | ADAS-cog | 20.0 (16.0) | GERRI | 2.1 (0.6) | CGI (item 1) | 3.5 (1.0) | HAMD | 5.1 (4.5) |
| Placebo | 154 | 20.5 (14.7) | 2.1 (0.6) | 3.4 (0.8) | 4.7 (4.2) | |||||
| Schneider et al32 | EGb 240 mg | 170 | ADAS-cog | 24.8 (12.7) | GERRI | 2.4 (0.5) | ADCS-CGIC | – | HAMD | 3.3 (3.1) |
| EGb 120 mg | 169 | 24.7 (12.7) | 2.4 (0.6) | – | 3.6 (3.2) | |||||
| Placebo | 174 | 25.0 (11.1) | 2.4 (0.6) | – | 3.4 (3.2) | |||||
| Nikolova et al14 | EGb 240 mg | 196 | SKT | 14.9 (4.3) | GBS-ADL | 2.3 (3.4) | GBS- total score | 26.0 (13.1) | HAMD | 9.5 (4.1) |
| Placebo | 201 | 15.4 (4.2) | 2.6 (3.6) | 26.7 (12.7) | 9.0 (3.8) | |||||
| Napryeyenko et al35 | EGb 240 mg | 198 | SKT | 15.6 (3.9) | GBS-ADL | 4.8 (3.9) | GBS- total score | 35.3 (9.1) | HAMD | 11.5 (4.3) |
| Placebo | 197 | 15.4 (3.7) | 4.9 (4.1) | 34.3 (8.7) | 11.8 (4.4) | |||||
| Ihl et al36 | EGb 240 mg | 202 | SKT | 16.7 (3.9) | ADL-IS | 1.9 (0.6) | ADCS-CGIC | – | HAMD | 9.1 (3.4) |
| Placebo | 202 | 17.2 (3.7) | 2.0 (0.5) | – | 9.8 (3.5) | |||||
| Herrschaft et al13 | EGb 240 mg | 200 | SKT | 15.1 (4.1) | ADL-IS | 1.7 (0.6) | ADCS-CGIC | – | HAMD | 9.3 (4.4) |
| Placebo | 202 | 15.3 (4.2) | 1.8 (0.6) | – | 9.4 (4.5) | |||||
Notes:
n includes all patients valid for evaluation of efficacy (full analysis set). Data are presented as the mean (standard deviation).
Abbreviations: ADAS-cog, cognitive subscale of the Alzheimer’s Disease Assessment Scale; ADL, activities of daily living; EGb, EGb 761®; CGI, Clinical Global Impression; CGIC, Clinical Global Impression of Change; ADCS-CGIC, Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change; NAB, Nuremberg Gerontopsychological Observation Scale; GERRI, Geriatric Evaluation by Relatives Rating Instrument; GBS, Gottfries-Bråne-Steen scale; GBS-ADL, Gottfries-Bråne-Steen Activities of Daily Living Scale; ADL-IS, Alzheimer’s Disease Activities of Daily Living International Scale; HAMD, Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; SKT, Short Cognitive Performance Test (Syndrom-Kurztest).